Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracochlear PLGA implants for simultaneous controlled release of multiple drugs.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Release mechanisms of PLGA-based drug delivery systems: A review.

International journal of pharmaceutics: X·2025
Same author

[Use of IL-1 inhibitors in the treatment of familial Mediterranean fever in pediatric rheumatology].

Zeitschrift fur Rheumatologie·2025
Same author

Release mechanisms of PLGA microparticles prepared using a microfluidics device or a beaker.

International journal of pharmaceutics: X·2025
Same author

Influence of the microstructure on the glass transition of amorphous materials.

International journal of pharmaceutics·2025
Same author

EVA implants for controlled drug delivery to the inner ear.

International journal of pharmaceutics: X·2024
Same journal

iRGD-Modified Peptide-Drug Conjugate Improves Brain Delivery and Antitumor Efficacy in Glioblastoma.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

A Δ‑Based Framework For Internal Release Limits In Plateau Stability Systems.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

Innovative Peptide Formulations for Cardiovascular Diseases Using Supercritical CO<sub>2</sub>: A Comprehensive Review and Potential Applications.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

An injectable nanoreinforced hydrogel for combined GDNF-loaded nanoparticles and mesenchymal stem cell therapy in Parkinson's disease.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

Lipid nanoparticles for Cas9 ribonucleoprotein delivery: design and evaluation of ionisable oligoamine-lipidoids.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same journal

Synthesis and biological evaluation of novel carbazole derivatives as broad-spectrum antibacterial agents to fight antimicrobial resistance (AMR).

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Multi-Scale Modification of Metallic Implants With Pore Gradients, Polyelectrolytes and Their Indirect Monitoring In vivo
12:19

Multi-Scale Modification of Metallic Implants With Pore Gradients, Polyelectrolytes and Their Indirect Monitoring In vivo

Published on: July 1, 2013

Controlled release implants based on cast lipid blends.

F Kreye1, F Siepmann, A Zimmer

  • 1Univ. Lille Nord de France, College of Pharmacy, 3, rue du Professeur Laguesse, 59006 Lille, France.

European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|April 6, 2011
PubMed
Summary
This summary is machine-generated.

Lipid:lipid blends offer tunable drug release profiles for controlled release implants. Adjusting blend ratios impacts release rates, with phase separation leading to unexpectedly rapid drug delivery.

More Related Videos

Platelet-Derived Extracellular Vesicle Functionalization of Ti Implants
04:16

Platelet-Derived Extracellular Vesicle Functionalization of Ti Implants

Published on: August 5, 2021

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

Multi-Scale Modification of Metallic Implants With Pore Gradients, Polyelectrolytes and Their Indirect Monitoring In vivo
12:19

Multi-Scale Modification of Metallic Implants With Pore Gradients, Polyelectrolytes and Their Indirect Monitoring In vivo

Published on: July 1, 2013

Platelet-Derived Extracellular Vesicle Functionalization of Ti Implants
04:16

Platelet-Derived Extracellular Vesicle Functionalization of Ti Implants

Published on: August 5, 2021

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Area of Science:

  • Pharmaceutical Sciences
  • Materials Science

Background:

  • Controlled drug delivery systems are crucial for therapeutic efficacy.
  • Lipid-based matrices offer potential for tunable drug release.
  • Understanding lipid miscibility is key to designing stable implants.

Purpose of the Study:

  • To investigate lipid:lipid blends as matrix formers for controlled release implants.
  • To explore the effect of varying lipid blend ratios on drug release kinetics.
  • To elucidate the mechanisms governing drug release from these lipid matrices.

Main Methods:

  • Preparation of implants using melting and casting techniques.
  • Characterization of lipid systems before and after exposure to release medium.
  • Mathematical modeling to analyze drug release mechanisms.
  • Differential scanning calorimetry (DSC) to assess lipid miscibility.

Main Results:

  • Tunable drug release periods from days to months achieved by adjusting lipid blend ratios (Precirol ATO 5:Dynasan 120).
  • Phase separation in specific blend ratios (20-25% Precirol) resulted in unexpectedly high drug release rates.
  • Drug release primarily diffusion-controlled only at low Precirol ATO 5 concentrations (5-10%).
  • Other release mechanisms include drug solubility limitations and matrix erosion.

Conclusions:

  • Lipid:lipid blends are versatile matrix formers for controlled release implants.
  • Careful consideration of lipid miscibility is essential to predict and control drug release.
  • Phase separation can significantly alter drug release kinetics, necessitating thorough characterization.